Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies

INTRODUCTION: In February 2018, OS320—an amantadine extended-release (ER) tablet formulation with once-daily morning administration—was approved for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adults. The purpose of this study was to describe three phase 1 studi...

Descripción completa

Detalles Bibliográficos
Autores principales: deVries, Tina, Dentiste, Angela, Handiwala, Lata, Jacobs, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858924/
https://www.ncbi.nlm.nih.gov/pubmed/31372936
http://dx.doi.org/10.1007/s40120-019-0144-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858924/
https://www.ncbi.nlm.nih.gov/pubmed/31372936
http://dx.doi.org/10.1007/s40120-019-0144-1

Ejemplares similares